Investment Highlights

As the first non-invasive, saliva-based glucose test for diabetes management, the Saliva Glucose Biosensor is a revolutionary technology that can free the 114 million diabetes patients in China from having to use painful and invasive blood monitoring devices to manage their condition, offering a better quality of life.

China has the world’s largest diabetes epidemic, with one quarter of the global diabetic population and close to 500 million people with prediabetes.

By eradicating the need for finger prick blood tests, the Saliva Glucose Biosensor will lead to improved glycemic control, better healthcare outcomes for patients and potentially massive cost savings for health systems.

The Saliva Glucose Biosensor is the first diagnostic test stemmed from the Biosensor Platform technology. Development has commenced to extend to an entire portfolio of tests including tumor markers, immunology and hormones.


GBSG Investor Relations


Press Releases

Download Introductory Brochure

Complete the form to receive a copy of the GBSG Introductory Brochure.